Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance.
| Autor: | Olson BP; VeraLight Inc., Albuquerque, New Mexico, USA. byron.olson@gmail.com, Matter NI, Ediger MN, Hull EL, Maynard JD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of diabetes science and technology [J Diabetes Sci Technol] 2013 Jul 01; Vol. 7 (4), pp. 990-1000. Date of Electronic Publication: 2013 Jul 01. |
| DOI: | 10.1177/193229681300700422 |
| Abstrakt: | Aim: We compare performance of noninvasive skin fluorescence spectroscopy (SFS), fasting plasma glucose (FPG), and hemoglobin A1c (A1C) for detection of abnormal glucose tolerance (AGT). Methods: The NSEEDS trial evaluated SFS, FPG, and A1C in an at-risk population of 479 previously undiagnosed subjects from nine US centers, each of whom received a 75 g, 2 h oral glucose tolerance test (OGTT). Skin fluorescence spectra were collected and analyzed with SCOUT DS® devices. Disease truth was AGT, defined as OGTT ≥140 mg/dl. Abnormal glucose tolerance sensitivity, false positive rate (FPR), and receiver operating characteristic (ROC) curves were computed for each measurement technique. Skin fluorescence spectroscopy reproducibility was also assessed. Results: The AGT sensitivity of SFS was 68.2%, higher than that of FPG (thresholds of 100 and 110 mg/dl) and A1C (thresholds of 5.7% and 6.0%). The FPR of SFS was 37.7%, comparable to A1C at the 5.7% threshold (30.7%). Partial ROC areas of SFS, FPG, and A1C were similar for FPRs of 20-50% (average sensitivities of 64.0%, 59.0%, and 68.6%, respectively). The interday coefficient of variation for SFS was 7.6%. Conclusions: Skin fluorescence spectroscopy has similar screening performance to FPG and A1C and is a viable approach for detection of AGT. (© 2013 Diabetes Technology Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|